Managing Neovascular Age-related Macular Degeneration (nAMD) Over 2 Years With a Treat and Extend (T&E) Regimen of 2 mg Intravitreal Aflibercept - a Randomized, Open-label, Active-controlled, Parallel-group Phase IV/IIIb Study (ARIES)
Active, no longer recruiting
Phase of Trial: Phase III/IV
Latest Information Update: 20 Nov 2017
At a glance
- Drugs Aflibercept (Primary)
- Indications Choroidal neovascularisation; Wet age-related macular degeneration
- Focus Therapeutic Use
- Acronyms ARIES
- Sponsors Bayer
- 13 Nov 2017 Status changed from recruiting to active, no longer recruiting.
- 30 Aug 2017 First results from this trial are expected to be available in 2018, according to a Bayer media release.
- 19 Dec 2016 Planned End Date changed from 1 Feb 2019 to 1 Apr 2019.